Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  Hsp90 inhibitor AT13387
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients with Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9878, NCI-2015-01411, PHI-80, NCT02535338
AT13387 in Treating Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9875, NCI-2015-01681, 15-XXX, 16-712, NCT02572453
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients with Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9557, NCI-2014-00615, 14-186, CTEP#9557, NCT02097225
HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients with Advanced Triple Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9876, NCI-2015-00866, OSU 15149, NCT02474173
Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9899, NCI-2015-01098, L9899, P9899, UK11143, NCT02503709
Start Over